Deal-driven Pipeline Strategy – Talk Bio

Actionable Insights Powered by AI

Merck KGaA Abandons Evobrutinib Development, Emphasizes Deal-Focused Pipeline Strategy

1 year ago talkbio0Tagged BTK Inhibitor, Deal-driven Pipeline Strategy, Discontinuation of Development, evobrutinib, Failed, Merck KGaA, Multiple Sclerosis, Phase 3 trials

Merck KGaA, Evobrutinib, BTK Inhibitor, Deal-driven Pipeline Strategy, Discontinuation of Development, Failed Phase 3 Trials, Multiple Sclerosis (MS) Treatment